8-K: Biofrontera Inc. Restructures Supply Agreement and Secures $16 Million in Private Placement

Biofrontera Inc. has significantly restructured its supply agreement with Biofrontera AG, reducing transfer prices and gaining control of US clinical trials, while also securing a private placement of up to $16 million.

Summary

• Biofrontera Inc. has amended its License and Supply Agreement (LSA) with Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH, effective February 13, 2024.
• The transfer price for Ameluz has been reduced to 25% through 2025, increasing to a maximum of 35% by 2032, subject to a minimum dollar amount per unit, from a previous structure of 50% of annual revenue up to $30 million, decreasing to 30% above $50 million.
• Responsibility for ongoing clinical trials will transfer to Biofrontera Inc. by June 1, 2024, including related contracts and key personnel.
• Failure to achieve annual minimum sales can now be a termination event, unless waived by Biofrontera Pharma and Bioscience.
• Biofrontera Inc. has also entered into a Release of Claims, releasing Biofrontera Pharma and Bioscience from liabilities related to clinical trials that Biofrontera Inc. will now manage.
• The company has secured a private placement with healthcare-focused institutional investors led by Rosalind Advisors, Inc.
• This includes $6.6 million in Series B-1 Convertible Preferred Stock and $1.4 million in warrants to purchase Series B-3 Convertible Preferred Stock, with a total potential gross proceeds of up to $16 million if all warrants are exercised.
• The Series B-1 Preferred Stock converts into 9,310,677 common shares at $0.7074 per share, and the Series B-3 Preferred Stock converts into 11,309,019 common shares at the same price.
• The warrants are exercisable upon achieving certain operational and commercial milestones, including the use of a new customer relationship management system and a 5% revenue increase, or within five years.
• The company intends to use the proceeds to fund general business operations and expedite the development of additional indications for Ameluz.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant restructuring of the supply agreement, the reduction in transfer prices, the increased control over clinical trials, and the successful capital raise. These factors are expected to improve the company's financial position and accelerate its growth trajectory.

Positives

• The reduced transfer price for Ameluz will significantly lower the company's cost of goods.
• Taking control of US clinical trials will allow for better cost management and efficiency.
• The private placement provides substantial funding for operations and development.
• The potential for new indications for Ameluz could lead to increased revenue.
• The restructuring of the supply agreement and the capital raise could lead to profitability in 2025.

Negatives

• Failure to achieve annual minimum sales can lead to termination of the agreement.
• The warrants are subject to certain milestones, which may not be achieved.
• Conversion of preferred stock is subject to shareholder approval for an increase in authorized shares.
• The company is reliant on the success of Ameluz and its expansion into new indications.

Risks

• The company's ability to achieve the milestones required for warrant exercise is uncertain.
• There is a risk that the company may not be able to achieve profitability in 2025.
• The company is subject to regulatory risks associated with clinical trials and approvals.
• The company is dependent on the success of Ameluz and its ability to expand into new indications.
• The company is subject to market risks and competition in the dermatological products sector.

Future Outlook

The company anticipates that the renegotiated terms of the supply agreement and the capital raised will accelerate the company's path to profitability in 2025. The company also expects a potential label change for Ameluz, allowing for up to three tubes per treatment, which is currently under review by the FDA with a user fee goal of October 4, 2024.

Management Comments

• Hermann Luebbert, CEO and Chairman of Biofrontera Inc., stated that the reduced transfer price will allow the company to finance R&D activities and continue its commercial growth.
• He also believes that controlling US clinical trials will enable better cost management and ensure efficiency, leading to new indications and increased revenue sooner.
• Management believes that the renegotiated terms along with the capital committed in the financing could be sufficient for the company achieving profitability in 2025.

Industry Context

This announcement reflects a strategic shift for Biofrontera Inc., moving towards greater independence from its former parent company and taking more control over its operations and product development. The restructuring of the supply agreement and the capital raise are aimed at improving the company's financial position and accelerating its growth in the competitive dermatological market. The focus on expanding the indications for Ameluz aligns with the industry trend of seeking new applications for existing products to maximize their market potential.

Comparison to Industry Standards

• The restructuring of the supply agreement is a significant move for Biofrontera Inc., as it reduces the cost of goods sold and provides more control over its supply chain. This is similar to other pharmaceutical companies that seek to optimize their cost structures to improve profitability.
• The transfer of clinical trial responsibilities to Biofrontera Inc. is a common practice in the pharmaceutical industry, as it allows companies to have more direct oversight and control over the development process. This is similar to companies like Galderma and Almirall, which manage their own clinical trials.
• The private placement of up to $16 million is a typical method for biotech companies to raise capital for research and development. This is comparable to other companies in the sector, such as Cassiopea and Cutera, which have also raised capital through private placements.
• The focus on expanding the indications for Ameluz is a common strategy in the pharmaceutical industry, as it allows companies to maximize the return on their investment in a particular product. This is similar to companies like Incyte and Regeneron, which have expanded the indications for their existing products.

Management Changes

Related Party Transactions

• The document details a significant restructuring of the License and Supply Agreement with Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH, which are related parties.
• The document also includes an addendum to the agreement which modifies a schedule of payments in relation to various financial obligations among the Company, Pharma, Bioscience, and Biofrontera AG.

Stakeholder Impact

• Shareholders will benefit from the potential for increased profitability and growth.
• Employees will be impacted by the transfer of clinical trial responsibilities and the potential for new job opportunities.
• Customers may benefit from the potential for new indications for Ameluz.
• Suppliers may be impacted by changes in the supply chain.
• Creditors may be impacted by the company's improved financial position.

Next Steps

• Biofrontera Inc. will complete the private placement, expected to close on or about February 21, 2024.
• The company will transfer responsibilities for ongoing clinical trials by June 1, 2024.
• The company will file a registration statement for the resale of common stock issued in connection with the private placement.
• The company will seek shareholder approval for an increase in authorized shares of common stock.
• The company will continue to pursue the development and approval of additional indications for Ameluz.

Key Dates

Keywords

Biofrontera, Ameluz, License Agreement, Clinical Trials, Private Placement, Convertible Preferred Stock, Warrants, Actinic Keratosis, Dermatology, Photodynamic Therapy